How I treat juvenile idiopathic arthritis: A state of the art review

被引：27

作者：

Cimaz, Rolando ^{[1
,2
]}

Marino, Achille ^{[1
,2
]}

Martini, Alberto ^{[3
,4
]}

机构：

[1] Azienda Oospedaliera Univ Anna Meyer, Florence, Italy

[2] Univ Firenze, Florence, Italy

[3] Ist Giannina Gaslini, Genoa, Italy

[4] Univ Genoa, Genoa, Italy

来源：

AUTOIMMUNITY REVIEWS | 2017年 / 16卷 / 10期

关键词：

MACROPHAGE ACTIVATION SYNDROME; ENTHESITIS-RELATED ARTHRITIS; PLACEBO-CONTROLLED TRIAL; LONG-TERM SAFETY; INTRAARTICULAR CORTICOSTEROID INJECTIONS; INTERLEUKIN-1 RECEPTOR ANTAGONIST; INFLIXIMAB PLUS METHOTREXATE; DOUBLE-BLIND; OPEN-LABEL; RHEUMATOID-ARTHRITIS;

D O I：

10.1016/j.autrev.2017.07.014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and an important cause of short and long-term disability. JIA encompasses several disease categories, each of which has distinct presentation, clinical manifestations, and, presumably, genetic background and etiopathogenesis. Correct choice and timely use of available medications to achieve early and sustained remission with as few side effects as possible remain challenges for the treating physician. This review aims to provide daily practical advice for the treatment of JIA patients on the basis of both our experience and existing recommendations. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：1008 / 1015

页数：8

共 122 条

[1] Enthesitis-related arthritis [J].

Aggarwal, Amita ;

Misra, Durga Prasanna .

CLINICAL RHEUMATOLOGY, 2015, 34 (11) :1839-1846

[2] Clinical Course and Prognostic Value of Disease Activity in the First Two Years in Different Subtypes of Juvenile Idiopathic Arthritis [J].

Albers, H. M. ;

Brinkman, D. M. C. ;

Kamphuis, S. S. M. ;

van Suijlekom-Smit, L. W. A. ;

van Rossum, M. A. J. ;

Hoppenreijs, E. P. A. H. ;

Girschick, H. J. ;

Wouters, C. ;

Saurenmann, R. K. ;

Houwing-Duistermaat, J. J. ;

Huizinga, T. W. J. ;

Schilham, M. W. ;

ten Cate, R. .

ARTHRITIS CARE & RESEARCH, 2010, 62 (02) :204-212

[3]

Alsufyani K, 2004, J RHEUMATOL, V31, P179

[4] Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials [J].

Amarilyo, Gil ;

Tarp, Simon ;

Foeldvari, Ivan ;

Cohen, Neta ;

Pope, Tracy D. ;

Woo, Jennifer M. P. ;

Christensen, Robin ;

Furst, Daniel E. .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 46 (03) :312-318

[5] MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis [J].

Anink, Janneke ;

Van Suijlekom-Smit, Lisette W. A. ;

Otten, Marieke H. ;

Prince, Femke H. M. ;

van Rossum, Marion A. J. ;

Dolman, Koert M. ;

Hoppenreijs, Esther P. A. H. ;

ten Cate, Rebecca ;

Ursu, Simona ;

Wedderburn, Lucy R. ;

Horneff, Gerd ;

Frosch, Michael ;

Vogl, Thomas ;

Gohar, Faekah ;

Foell, Dirk ;

Roth, Johannes ;

Holzinger, Dirk .

ARTHRITIS RESEARCH & THERAPY, 2015, 17

[6] Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial [J].

Baeten, Dominique ;

Baraliakos, Xenofon ;

Braun, Juergen ;

Sieper, Joachim ;

Emery, Paul ;

van der Heijde, Desiree ;

McInnes, Iain ;

van Laar, Jacob M. ;

Landewe, Robert ;

Wordsworth, Paul ;

Wollenhaupt, Juergen ;

Kellner, Herbert ;

Paramarta, Jacqueline ;

Wei, Jiawei ;

Brachat, Arndt ;

Bek, Stephan ;

Laurent, Didier ;

Li, Yali ;

Wang, Ying A. ;

Bertolino, Arthur P. ;

Gsteiger, Sandro ;

Wright, Andrew M. ;

Hueber, Wolfgang .

LANCET, 2013, 382 (9906) :1705-1713

[7] The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis [J].

Bartoli, M. ;

Taro, M. ;

Magni-Manzoni, S. ;

Pistorio, A. ;

Traverso, F. ;

Viola, S. ;

Magnani, A. ;

Gasparini, C. ;

Martini, A. ;

Ravelli, A. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) :370-374

[8] Clinical Outcomes After Withdrawal of Anti-Tumor Necrosis Factor α Therapy in Patients With Juvenile Idiopathic Arthritis: A Twelve-Year Experience [J].

Baszis, Kevin ;

Garbutt, Jane ;

Toib, Dana ;

Mao, Jingnan ;

King, Allison ;

White, Andrew ;

French, Anthony .

ARTHRITIS AND RHEUMATISM, 2011, 63 (10) :3163-3168

[9] 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features [J].

Beukelman, Timothy ;

Patkar, Nivedita M. ;

Saag, Kenneth G. ;

Tolleson-Rinehart, Sue ;

Cron, Randy Q. ;

DeWitt, Esi Morgan ;

Ilowite, Norman T. ;

Kimura, Yukiko ;

Laxer, Ronald M. ;

Lovell, Daniel J. ;

Martini, Alberto ;

Rabinovich, C. Egla ;

Ruperto, Nicolino .

ARTHRITIS CARE & RESEARCH, 2011, 63 (04) :465-482

[10] Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy [J].

Brachat, Arndt H. ;

Grom, Alexei A. ;

Wulffraat, Nico ;

Brunner, Hermine I. ;

Quartier, Pierre ;

Brik, Riva ;

McCann, Liza ;

Ozdogan, Huri ;

Rutkowska-Sak, Lidia ;

Schneider, Rayfel ;

Gerloni, Valeria ;

Harel, Liora ;

Terreri, Maria ;

Houghton, Kristin ;

Joos, Rik ;

Kingsbury, Daniel ;

Lopez-Benitez, Jorge M. ;

Bek, Stephan ;

Schumacher, Martin ;

Valentin, Marie-Anne ;

Gram, Hermann ;

Abrams, Ken ;

Martini, Alberto ;

Lovell, Daniel J. ;

Nirmala, Nanguneri R. ;

Ruperto, Nicolino .

ARTHRITIS RESEARCH & THERAPY, 2017, 19

← 1 2 3 4 5 6 7 8 9 10 →